In this study, we demonstrated significantly elevated levels of XBP1 and XBP1s in HR+/HER2− breast cancer, which were associated with an unfavorable therapeutic response and poor prognosis in patients who received the combination treatment of CDK4/6 inhibitors plus endocrine therapy. Here, CDK4 is linked to breast cancer.